The report provides a detailed analysis essential for establishing a sarilumab production plant. It encompasses all critical aspects necessary for sarilumab production, including the cost of sarilumab production, sarilumab plant cost, sarilumab production costs, and the overall sarilumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a sarilumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Sarilumab is a synthetic human antibody that blocks the IL-6 receptor. This stops inflammation signals in diseases where the immune system attacks the body, like rheumatoid arthritis. It is FDA-approved for treating moderately to severely active rheumatoid arthritis (RA) in adults who don't respond to other disease-modifying antirheumatic drugs (DMARDs). It is used for polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids, and polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg or more. It is administered via subcutaneous injection every two weeks, which reduces joint pain, swelling, and acute-phase reactants. Its common side effects include infections, elevated liver enzymes, and neutropenia requiring monitoring.
The sarilumab market is driven by increasing cases of autoimmune diseases like rheumatoid arthritis. The growing elderly population vulnerable to such conditions, growing awareness of biologic treatments' effectiveness, and improvements in healthcare systems contribute to its market growth. The supply chain instabilities, because of shortages, limited supplier options dominated by key players, and high pricing sensitivity in hospitals and clinics impacts industrial sarilumab procurement. The competitive bidding for cost control, regulatory requirements, and prequalified suppliers impacts its sourcing. Other factors like reimbursement policies, regulatory approvals, emerging biosimilars, healthcare budgets, and emerging market policies further affect its market dynamics.
Raw Material for Sarilumab Production
According to the sarilumab production plant project report, the key raw materials used in the production of sarilumab include Chinese hamster ovary (CHO) cells and cell culture media.
Production Process of Sarilumab
The extensive sarilumab production cost report consists of the following major industrial production process:
- From Chinese hamster ovary (CHO) cells: The production process of sarilumab involves recombinant DNA technology using Chinese Hamster Ovary (CHO) cells. The production process starts with cell expansion and production in bioreactors. This is followed by harvesting, filtration to remove cells and debris, and purification through protein A. The drug product is then prepared by thawing and pooling the bulk drug substance, pre-filtration, sterile filtration, etc., giving pure sarilumab.
Sarilumab has the molecular formula of C6388H9918N1718O1998S44 and a molecular weight of 150 kDa. Its structure is a heterotetramer, which is made of two disulfide-linked heavy chains and two kappa light chains. It features a single N-linked glycosylation site in the Fc region's CH2 domain. It has a melting point of 69–80 degrees Celsius and an isoelectric point between 6.6 and 7.2. This contributes to its stability as a biologic for subcutaneous administration. It targets the IL-6 receptor with high specificity through complementarity-determining regions in its variable domains. It binds both soluble and membrane-bound forms to block IL-6 signalling, with pharmacokinetics showing AUC values of 202–395 mg·day/L based on dosing.
